Bio-Rad Launches The First Fully-Automated 5th Generation HIV Test
Hercules, CA (Marketwired) - Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.B), a global manufacturer and distributor of life science research and clinical diagnostic products, today announced the launch of its BioPlex® 2200 HIV Ag-Ab kit, the company's 5th generation HIV test for markets outside the U.S.
Similar to 4th generation assays, the BioPlex 2200 HIV Ag-Ab kit offers early detection of HIV by detecting HIV antigens (proteins that are part of the HIV virus) and HIV antibodies (proteins that are produced by the body to fight the HIV infection). In addition to the early detection offered by 4th generation assays, the 5th generation BioPlex HIV Ag-Ab kit provides more information by specifically identifying which individual HIV 1 and HIV 2 marker is positive. This valuable additional information indicates if the patient was recently infected and can help guide follow-up testing, saving laboratory time and resources and delivering patient results faster.
During the first 6 months after infection virus levels are higher and the risk of transmission is greater. With a 5th generation test, clinicians can use the identification of the primary HIV-1 antigen to help identify patients with early infection, information that is not available using a 4thgeneration test. Early treatment of these patients and outreach to those they may have infected reduces the risk of further transmission.
The most recent published data estimates over 33 million people are living with HIV/AIDS and 1.7 million people die of AIDS annually. Early detection and treatment of the disease are key to reducing the spread of HIV.
"Bio-Rad is pleased to launch the next generation in HIV screening," said John Goetz, Bio-Rad Executive Vice President and President, Clinical Diagnostics Group. "Bio-Rad has a long history of providing laboratories the tools that they need for HIV detection."
The release of the BioPlex 2200 HIV Ag-Ab kit expands the BioPlex 2200's growing infectious disease menu. The BioPlex 2200 system is the first and only fully-automated, random access multiplex testing system and provides clinical laboratories with the capability to rapidly process or "multiplex" multiple individual tests that are traditionally processed separately. The BioPlex 2200 system conserves patient sample volume, helps consolidate workstations, and simplifies workflow.
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.B) designs, manufactures, and distributes a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs approximately 7,750 people worldwide and had revenues exceeding $2.1 billion in 2013. For more information, visit our website at www.bio-rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.
SOURCE: Bio-Rad Laboratories